351 related articles for article (PubMed ID: 25896127)
21. Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States.
Bosch NA; Teja B; Wunsch H; Walkey AJ
Ann Am Thorac Soc; 2021 Dec; 18(12):2049-2057. PubMed ID: 33975530
[No Abstract] [Full Text] [Related]
22. Impact of Norepinephrine Weight-Based Dosing Compared With Non-Weight-Based Dosing in Achieving Time to Goal Mean Arterial Pressure in Obese Patients With Septic Shock.
Vadiei N; Daley MJ; Murthy MS; Shuman CS
Ann Pharmacother; 2017 Mar; 51(3):194-202. PubMed ID: 27886982
[TBL] [Abstract][Full Text] [Related]
23. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
[TBL] [Abstract][Full Text] [Related]
24. Delayed vasopressor initiation is associated with increased mortality in patients with septic shock.
Colon Hidalgo D; Patel J; Masic D; Park D; Rech MA
J Crit Care; 2020 Feb; 55():145-148. PubMed ID: 31731173
[TBL] [Abstract][Full Text] [Related]
25. Implications of Statin Use on Vasopressor Therapy in the Setting of Septic Shock.
McPheeters CM; Wiedmar JA; Pinkston CM; Weant KA
Hosp Pharm; 2018 Jun; 53(3):152-156. PubMed ID: 30147135
[No Abstract] [Full Text] [Related]
26. Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death.
Brand DA; Patrick PA; Berger JT; Ibrahim M; Matela A; Upadhyay S; Spiegler P
J Pain Symptom Manage; 2017 May; 53(5):938-943. PubMed ID: 28062334
[TBL] [Abstract][Full Text] [Related]
27. Fever control using external cooling in septic shock: a randomized controlled trial.
Schortgen F; Clabault K; Katsahian S; Devaquet J; Mercat A; Deye N; Dellamonica J; Bouadma L; Cook F; Beji O; Brun-Buisson C; Lemaire F; Brochard L
Am J Respir Crit Care Med; 2012 May; 185(10):1088-95. PubMed ID: 22366046
[TBL] [Abstract][Full Text] [Related]
28. Mortality trends in U.S. adults with septic shock, 2005-2011: a serial cross-sectional analysis of nationally-representative data.
Goto T; Yoshida K; Tsugawa Y; Filbin MR; Camargo CA; Hasegawa K
BMC Infect Dis; 2016 Jun; 16():294. PubMed ID: 27301657
[TBL] [Abstract][Full Text] [Related]
29. Timing of vasopressor initiation and mortality in septic shock: a cohort study.
Beck V; Chateau D; Bryson GL; Pisipati A; Zanotti S; Parrillo JE; Kumar A;
Crit Care; 2014 May; 18(3):R97. PubMed ID: 24887489
[TBL] [Abstract][Full Text] [Related]
30. Impact of a recent chemotherapy on the duration and intensity of the norepinephrine support during septic shock.
Schnell D; Besset S; Lengliné E; Maziers N; Zafrani L; Reuter D; Moreau AS; Canet E; Lemiale V; Azoulay E
Shock; 2013 Feb; 39(2):138-43. PubMed ID: 23324882
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
Haan BJ; Cadiz ML; Natavio AM
Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
[No Abstract] [Full Text] [Related]
32. CT-proAVP IS NOT A GOOD PREDICTOR OF VASOPRESSOR NEED IN SEPTIC SHOCK.
Laribi S; Lienart D; Castanares-Zapatero D; Collienne C; Wittebole X; Laterre PF
Shock; 2015 Oct; 44(4):330-5. PubMed ID: 26196839
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock.
Wu JY; Stollings JL; Wheeler AP; Semler MW; Rice TW
Ann Pharmacother; 2017 Jan; 51(1):13-20. PubMed ID: 27630192
[TBL] [Abstract][Full Text] [Related]
34. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study.
Bauer SR; Lam SW; Cha SS; Oyen LJ
J Crit Care; 2008 Dec; 23(4):500-6. PubMed ID: 19056013
[TBL] [Abstract][Full Text] [Related]
35. Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure.
Conrad M; Perez P; Thivilier C; Levy B
J Crit Care; 2015 Aug; 30(4):739-43. PubMed ID: 25900257
[TBL] [Abstract][Full Text] [Related]
36. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.
Whitson MR; Mo E; Nabi T; Healy L; Koenig S; Narasimhan M; Mayo PH
Chest; 2016 Jun; 149(6):1380-3. PubMed ID: 26953217
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock.
Patel GP; Grahe JS; Sperry M; Singla S; Elpern E; Lateef O; Balk RA
Shock; 2010 Apr; 33(4):375-80. PubMed ID: 19851126
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
[TBL] [Abstract][Full Text] [Related]
39. Severe sepsis and septic shock in patients with pre-existing non-cardiac pulmonary hypertension: contemporary management and outcomes.
Tsapenko MV; Herasevich V; Mour GK; Tsapenko AV; Comfere TB; Mankad SV; Cartin-Ceba R; Gajic O; Albright RC
Crit Care Resusc; 2013 Jun; 15(2):103-9. PubMed ID: 23931041
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting.
Ragoonanan D; Allen B; Cannon C; Rottman-Pietrzak K; Bello A
Ann Pharmacother; 2022 Mar; 56(3):264-270. PubMed ID: 34109850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
